Table 1

Demographic and baseline characteristics of patients in RA-BEAM (MTX-IR patients with established RA) and RA-BEGIN (csDMARD-naïve patients with early RA) stratified by averaged CDAI

RA-BEAMRA-BEGIN
CDAI ≤10CDAI >10CDAI ≤10CDAI >10
PBO (n=61)Bari 4 mg (n=171)ADA (n=98)PBO (n=257)Bari 4 mg (n=236)ADA (n=164)MTX (n=53)Bari 4 mg (n=72)Bari 4 mg ± MTX (n=104)MTX (n=81)Bari 4 mg (n=53)Bari 4 mg ± MTX (n=62)
Age, years54.6±12.453.0±11.952.1±11.852.5±11.552.7±12.353.2±12.250.9±13.750.3±13.045.9±13.449.7±13.251.3±13.051.0±13.0
Female, n (%)49 (80.3)134 (78.4)73 (74.5)202 (78.6)179 (75.8)125 (76.2)37 (69.8)55 (76.4)73 (70.2)58 (71.6)42 (79.2)49 (79.0)
BMI, kg/m2 28.0±6.226.3±5.626.1±5.226.8±6.627.2±6.226.6±5.427.1±6.327.7±6.625.8±5.326.5±6.625.3±6.326.8±6.7
Smoker, yes, n (%)8 (13.1)39 (22.8)18 (18.4)58 (22.6)53 (22.5)38 (23.2)8 (15.1)18 (25.0)20 (19.2)16 (19.8)11 (20.8)15 (24.2)
Duration of RA from diagnosis, years8.8±7.39.0±8.47.8±7.48.9±7.88.3±8.68.5±8.20.5±1.01.5±3.31.1±2.21.4±4.02.0±4.41.8±3.7
hsCRP, mg/L13.7±14.518.9±19.418.6±16.717.9±17.225.0±24.622.0±20.017.2±14.619.8±16.326.6±28.725.2±22.624.2±23.522.0±28.1
CDAI28.5±10.633.2±10.632.4±13.338.8±12.441.0±11.440.3±11.938.6±13.735.3±13.137.9±12.139.7±12.642.3±11.342.9±13.5
HAQ-DI1.2±0.71.4±0.71.3±0.71.6±0.61.7±0.71.7±0.61.6±0.71.5±0.81.6±0.71.7±0.71.7±0.61.7±0.7
RF-positive*, n (%)55 (90.2)157 (91.8)90 (91.8)238 (92.6)211 (89.4)150 (91.5)50 (94.3)72 (100)100 (96.2)79 (97.5)52 (98.1)57 (91.9)
ACPA-positive†, n (%)53 (86.9)150 (87.7)89 (90.8)221 (86.0)212 (89.8)145 (88.4)47 (88.7)68 (94.4)98 (94.2)77 (95.1)46 (86.8)53 (85.5)
Pain assessment47.6±23.258.3±21.755.2±24.560.6±21.163.6±21.962.5±21.862.4±24.459.4±24.261.2±22.465.5±25.164.1±19.368.0±21.2
mTSS34.3±41.535.9±42.734.7±42.044.7±50.647.1±55.450.2±56.48.4±21.47.4±12.88.6±16.213.1±17.617.0±34.617.6±26.4
  • Data are mean±SD or n (%).

  • Averaged CDAI responses in RA-BEAM calculated as the mean of postbaseline measurements at weeks 4, 12, 16, 20 and 24 and in RA-BEGIN as the mean of postbaseline measurements at weeks 4, 12, 16, 20, 24, 32, 40 and 52.

  • *RF-positive >14 units/mL (ULN).

  • †ACPA-positive >10 units/mL (ULN).

  • ACPA, anticyclic citrullinated peptide antibody; ADA, adalimumab; Bari, baricitinib; BMI, body mass index; CDAI, Clinical Disease Activity Index; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; HAQ-DI, Health Assessment Questionnaire-Disability Index; hsCRP, high-sensitivity C reactive protein; mITT, modified intent-to-treat; mTSS, modified Total Sharp Score; MTX-IR, inadequate response to methotrexate; n, number of mITT completers; PBO, placebo; RA, rheumatoid arthritis; RF, rheumatoid factor; ULN, upper limit of normal.